Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: A double blind, randomized trial

Heinrich, Kurt F. J.; Klieser, E.; Lehmann, E.; Kinzler, E.; Hruschka, H

doi:10.1016/0278-5846(94)90029-9

Cited by 68 publications

(27 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Além disso, outros ECRs pequenos revelaram eficácia global comparável (Chiu et al, 1976;Guirguis et al, 1977;Gelenberg e Doller, 1979) ou superior à da clorpromazina (Shopdin et al, 1979). A clozapina foi tão eficaz quanto o haloperidol ou a risperidona (Heinrich et al, 1994) nos episódios agudos de esquizofrenia e superior à clorpromazina em pacientes no primeiro episódio (Lieberman et al, 2003). Em resumo, há evidência para a eficácia da clozapina nos episódios agudos de esquizofrenia (Nível B), mas, por causa de seu perfil de efeitos colaterais, especialmente efeitos adversos hematológicos, não é recomendada no tratamento de primeira linha da esquizofrenia aguda.…”

Section: Eficácia Dos Antipsicóticos De Segunda Geraçãounclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoEstas diretrizes para o tratamento biológico da esquizofrenia foram desenvolvidas pela Força-Tarefa da Federação Mundial das Sociedades de Psiquiatria Biológica (World Federation of Societies of Biological Psychiatry, WFSBP). A meta fixada durante o desenvolvimento destas diretrizes foi rever sistematicamente todas as evidências disponíveis referentes ao tratamento da esquizofrenia, tanto no âmbito clínico como científico, e chegar a um consenso sobre as principais recomendações para a prática psiquiátrica. Estas diretrizes são destinadas a todos os médicos que atendem e tratam de pacientes portadores de esquizofrenia. Os dados usados para desenvolver estas diretrizes foram extraídos primariamente de vários painéis e diretrizes nacionais de tratamento para esquizofrenia, assim como de metanálises, revisões e estudos clínicos randomizados sobre a eficácia do tratamento farmacológico e de outras intervenções terapêuticas biológicas, identificadas por uma busca nas bases de dados MedLine e Biblioteca Cochrane. A literatura identificada foi avaliada no que diz respeito à solidez das evidências a favor da eficácia de uma dada intervenção e,

show abstract

Section: Eficácia Dos Antipsicóticos De Segunda Geraçãounclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

show abstract

“…Its efficacy was demonstrated in acutely psychotic patients in seven clinical investigations [12][13][14][15][16][17][18] and it has rapidly become one of the most widely prescribed antipsychotics in the developed world. It is increasingly used in first-line therapy at the initial onset of psychosis.…”

Section: Risperidonementioning

confidence: 99%

Future therapies for schizophrenia

Sodhi¹,

Murray²

1997

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Despite decades of research, the aetiology of schizophrenia remains elusive. However, the recent success of atypical antipsychotic drugs such as clozapine and risperidone has broken a 30 year trend during which pharmaceutical companies focused solely on D2 receptor antagonism in their quest for new drug treatments for schizophrenia. In the next few years, at least four other new atypical antipsychotics, olanzapine, sertindole, seroquel and ziprasidone, will be introduced throughout the developed world. It is likely that atypical compounds such as these will largely displace the typical neuroleptics, which provide only limited efficacy and produce unpleasant side-effects. The majority of the patents taken out in recent years remain focussed on the traditional notions of dopamine blockade, but there is an increasing trend in industry to select D 1 , D 3 and D 4 receptors as targets for potential drugs, rather than the D2 subtype. Greater emphasis is now being placed on the serotonergic hypothesis of schizophrenia, as more ligands selective for serotonin receptors are developed. A large number of companies have combined both theories in an effort to produce improved versions of clozapine; thus the serotonin-dopamine antagonist (SDA) class of compounds has emerged. Such drugs certainly display fewer extrapyramidal side-effects than traditional neuroleptics and there is considerable hope that they may prove more effective in the treatment of negative symptoms. Patent applications for radically different compounds have also appeared during 1995 and 1996, including some based on the glutamatergic and developmental theories of schizophrenia. These potential new therapies are reviewed. Exp. Opin. Ther. Patents (1997) 7(2):151-165

show abstract

“…Three studies have been conducted comparing the therapeutic effects of risperidone to clozapine in the treatment of psychotic symptoms (7,25,37). Each of these investigations concluded that the medications were equally effective, but these findings are tempered somewhat by significant limitations in study design, including a small number of enrolled subjects and brief duration of treatment.…”

Section: Comparison With Other Atypical Antipsychoticsmentioning

confidence: 99%